Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Belite Bio, Inc - American Depositary Shares
(NQ:
BLTE
)
80.23
-2.22 (-2.69%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
72,894
Open
82.00
Bid (Size)
72.56 (4)
Ask (Size)
81.56 (3)
Prev. Close
82.45
Today's Range
78.00 - 82.07
52wk Range
31.00 - 86.53
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
October 14, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
October 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Performance
YTD
+87.63%
+87.63%
1 Month
+23.47%
+23.47%
3 Month
+64.04%
+64.04%
6 Month
+76.06%
+76.06%
1 Year
+112.76%
+112.76%
More News
Read More
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
September 10, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 12, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Insights into Belite Bio's Upcoming Earnings
November 11, 2024
Via
Benzinga
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
November 05, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
November 03, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
September 26, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio to Participate in Three Upcoming Investor Conferences
September 03, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
September 17, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
September 01, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024
August 09, 2024
Via
InvestorPlace
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 09, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
August 05, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Present at the JonesHealthcare Seaside Summit
July 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
June 12, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
May 14, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
May 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
May 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
May 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.